Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 4/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761192 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL10106331 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL10106427 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1023170 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL641026 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL19082743 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219189 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219188 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22433392 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20636193 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020234726-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-9670209-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160039819-A1 | MUSCARINIC AGONISTS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | CHRM2 1726/4885CHRM1 1613/4885CHRM3 599/4885 |
| US-20160039819-A1 | MUSCARINIC AGONISTS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.